Teroxirone

Teroxirone

SCHEMBL4472568

O=c1n(CC2CO2)c(=O)n(C[C@@H]2CO2)c(=O)n1CC1CO1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 1.00
HBB P68871 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
DHFR P00374 1/20 0.48
MAPT P10636 1/20 0.39
ALDH1A1 P00352 2/20 0.35
TSHR P16473 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
CDK4 P11802 1/20 0.33
CCND1 P24385 1/20 0.33
CCND2 P30279 1/20 0.33
CCND3 P30281 1/20 0.33
KDM4E B2RXH2 1/20 0.32
CYP3A4 P08684 1/20 0.31
MAPK14 Q16539 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Teroxirone SCHEMBL2097375 1.00 TP53 (1.00) TP53HBBSMN1; SMN2DHFRMAPT
Teroxirone SCHEMBL4452999 1.00 TP53 (1.00) TP53HBBSMN1; SMN2DHFRMAPT
Teroxirone SCHEMBL2097151 1.00 TP53 (1.00) TP53HBBSMN1; SMN2DHFRMAPT
Teroxirone SCHEMBL4461477 1.00 TP53 (1.00) TP53HBBSMN1; SMN2DHFRMAPT
Teroxirone SCHEMBL4932 1.00 TP53 (1.00) TP53HBBSMN1; SMN2DHFRMAPT
Teroxirone SCHEMBL4470513 1.00 TP53 (1.00) TP53HBBSMN1; SMN2DHFRMAPT
SCHEMBL10963410 0.93 TP53 (0.86) TP53HBBSMN1; SMN2DHFRMAPT
SCHEMBL17804388 0.89 TP53 (0.78) TP53HBBSMN1; SMN2DHFRMAPT
Teroxirone SCHEMBL10993252 0.89 TP53 (0.78) TP53HBBSMN1; SMN2DHFRMAPT
SCHEMBL1715098 0.89 TP53 (0.78) TP53HBBSMN1; SMN2DHFRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9416116-B2 Method of preparation of metaxalone AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2016-08-16 US disclosed
US-9376322-B2 Process for producing colloidal silica particles NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-06-28 US disclosed
US-9310681-B2 Negative resist composition and patterning process using same SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-04-12 US disclosed
US-20150376018-A1 COLLOIDAL SILICA PARTICLES, PROCESS FOR PRODUCING THE SAME, AND ORGANIC SOLVENT-DISPERSED SILICA SOL, POLYMERIZABLE COMPOUND-DISPERSED SILICA SOL, AND DICARBOXYLIC ANHYDRIDE-DISPERSED SILICA SOL EACH OBTAINED FROM THE SAME NISSAN CHEMICAL IND LTD (JP) 2015-12-31 US disclosed
US-20150353684-A1 HIGHLY SOLUBLE TRIS- (2, 3-EPOXYPROPYL)- ISOCYANURATE AND METHOD FOR PRODUCING SAME NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2015-12-10 US disclosed
US-20150284345-A1 METHOD OF PREPARATION OF METAXALONE AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2015-10-08 US disclosed
US-8865391-B2 Chemically amplified negative resist composition, photo-curable dry film, making method, pattern forming process, and electric/electronic part protecting film SHIN-ETSU CHEMICAL CO., LTD. (JP) 2014-10-21 US disclosed
US-20140308527-A1 ISOCYANURATE EPOXY COMPOUND HAVING ALKOXYSILYL GROUP, METHOD OF PREPARING SAME, COMPOSITION INCLUDING SAME, CURED PRODUCT OF THE COMPOSITION, AND USE OF THE COMPOSITION KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) 2014-10-16 US disclosed
US-8765835-B2 Epdxy resin composition having monocyclic aliphatic hydrocarbon ring NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2014-07-01 US disclosed
US-20130261160-A1 METHOD OF PREPARATION OF METAXALONE AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2013-10-03 US disclosed
US-6444814-B1 REACTING EPICHLOROHYDRIN AND ISOCYANURIC ACID NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2002-09-03 US disclosed
US-20020111485-A1 Optically active epoxy compound NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2002-08-15 US disclosed
EP-0952155-B1 Beta-form tris-(2,3-epoxypropyl)-isocyanurate crystals and process for their production NISSAN CHEMICAL IND LTD (JP) 2002-07-24 EP disclosed
US-20020045752-A1 Method for reducing an organic solvent remaining in beta-form tris- (2,3,-epoxypropyl) - isocyanurate crystals NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2002-04-18 US disclosed
US-20010018517-A1 Method for reducing organic solvents remaining in tris-(2,3-epoxypropyl)-isocyanurate crystals NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2001-08-30 US disclosed
EP-1061080-A1 OPTICALLY ACTIVE EPOXY COMPOUND Nissan Chemical Industries, Ltd. (JP) 2000-12-20 EP disclosed
US-6124454-A β-form tris-(2, 3-epoxypropyl)-isocyanurate crystals and process for their production NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2000-09-26 US disclosed
US-6111104-A PULVERIZING THE SOLVENT-WASHED CRYSTAL PARTICLES WHILE EVAPORATING SOLVENT AND EPICHLOROHYDRIN REACTANT FROM THE SURFACES OF THE PARTICLES, E.G. MACHINE PULVERIZATION IN A GAS STREAM. NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2000-08-29 US disclosed
EP-0984011-A1 Method for reducing an organic solvent remaining in tris-(2,3-expoxy-propyl)-isocyanurate crystals NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 2000-03-08 EP disclosed
EP-0952155-A1 Beta-form tris-(2,3-epoxypropyl)-isocyanurate crystals and process for their production NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1999-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140308527-A1 ISOCYANURATE EPOXY COMPOUND HAVING ALKOXYSILYL GROUP, METHOD OF PREPARING SAME, COMPOSITION INCLUDING SAME, CURED PRODUCT OF THE COMPOSITION, AND USE OF THE COMPOSITION ESD, FTO, TET1 TP53 3703/4885HBB 1403/4885SMN1; SMN2 2726/4885
US-20150284345-A1 METHOD OF PREPARATION OF METAXALONE MTX1, MTX2, APOL1 TP53 3906/4885HBB 865/4885SMN1; SMN2 4039/4885
US-20130261160-A1 METHOD OF PREPARATION OF METAXALONE MTX1, MTX2, APOL1 TP53 3906/4885HBB 865/4885SMN1; SMN2 4039/4885
US-20020111485-A1 Optically active epoxy compound TREH, APEH, EPHX2 TP53 4731/4885HBB 441/4885SMN1; SMN2 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.